Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2 Pt 2
pubmed:dateCreated
1994-4-26
pubmed:abstractText
We tested the hypothesis that NO synthase inhibition with N omega-nitro-L-arginine methyl ester (L-NAME) and alpha 2-adrenoreceptor stimulation with dexmedetomidine (Dex) decreases the cerebral blood flow (CBF) response to hypoxia. In isoflurane-anesthetized dogs, CBF was measured during two episodes of hypoxic hypoxia. In a control group (n = 6), CBF increased similarly from 83 +/- 4 to 210 +/- 30 ml.min-1 x 100 g-1 and from 88 +/- 7 to 205 +/- 27 (+/- SE) ml.min-1 x 100 g-1 during two hypoxic episodes. In a second group (n = 6), hypoxia increased CBF from 88 +/- 15 to 204 +/- 38 ml.min-1 x 100 g-1. Dex (10 micrograms/kg i.v.) reduced normoxic CBF to 54 +/- 8 ml.min-1 x 100 g-1, and subsequent hypoxia increased CBF to 97 +/- 14 ml.min-1 x 100 g-1. In a third group pretreated with L-NAME (40 mg/kg i.v.) 1 h before anesthesia (n = 6), normoxic CBF was less than in the control group (52 +/- 2 vs. 83 +/- 4 ml.min-1 x 100 g-1). Hypoxia increased CBF to 177 +/- 13 ml.min-1 x 100 g-1. Dex after L-NAME further decreased normoxic CBF to 37 +/- 3 ml.min-1 x 100 g-1, and subsequent hypoxia increased CBF to 106 +/- 18 ml.min-1 x 100 g-1. Dex, L-NAME, and Dex + L-NAME each reduced cerebral O2 transport (CBF x arterial O2 content) during normoxia, but the increase in CBF during hypoxia was sufficient to prevent further decreases in O2 transport. Thus the response to hypoxia remained proportional to normoxic levels of CBF.(ABSTRACT TRUNCATED AT 250 WORDS)
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0002-9513
pubmed:author
pubmed:issnType
Print
pubmed:volume
266
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
H476-82
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:7511347-Adrenergic alpha-Agonists, pubmed-meshheading:7511347-Amino Acid Oxidoreductases, pubmed-meshheading:7511347-Animals, pubmed-meshheading:7511347-Anoxia, pubmed-meshheading:7511347-Arginine, pubmed-meshheading:7511347-Brain, pubmed-meshheading:7511347-Carbon Dioxide, pubmed-meshheading:7511347-Cerebrovascular Circulation, pubmed-meshheading:7511347-Dogs, pubmed-meshheading:7511347-Hydrogen-Ion Concentration, pubmed-meshheading:7511347-Imidazoles, pubmed-meshheading:7511347-Medetomidine, pubmed-meshheading:7511347-NG-Nitroarginine Methyl Ester, pubmed-meshheading:7511347-Nitric Oxide, pubmed-meshheading:7511347-Nitric Oxide Synthase, pubmed-meshheading:7511347-Organ Specificity, pubmed-meshheading:7511347-Oxygen, pubmed-meshheading:7511347-Oxygen Consumption, pubmed-meshheading:7511347-Partial Pressure, pubmed-meshheading:7511347-Receptors, Adrenergic, alpha-2, pubmed-meshheading:7511347-Regional Blood Flow
pubmed:year
1994
pubmed:articleTitle
Hypoxia, alpha 2-adrenergic, and nitric oxide-dependent interactions on canine cerebral blood flow.
pubmed:affiliation
Department of Anesthesiology/Critical Care Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.